GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Goodwill-to-Asset

NYMXF (Nymox Pharmaceutical) Goodwill-to-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Nymox Pharmaceutical's Goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil. Nymox Pharmaceutical's Total Assets for the quarter that ended in Sep. 2024 was $0.62 Mil.


Nymox Pharmaceutical Goodwill-to-Asset Historical Data

The historical data trend for Nymox Pharmaceutical's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Goodwill-to-Asset Chart

Nymox Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Goodwill-to-Asset

For the Biotechnology subindustry, Nymox Pharmaceutical's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Goodwill-to-Asset falls into.


;
;

Nymox Pharmaceutical Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Nymox Pharmaceutical's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/0.627
=

Nymox Pharmaceutical's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill to Asset (Q: Sep. 2024 )=Goodwill/Total Assets
=0/0.624
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Nymox Pharmaceutical Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical Headlines

From GuruFocus

NYMOX Update

By Marketwired 07-07-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023